Orchestra BioMed Holdings Inc (OBIO)

Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW HOPE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra...

Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference

NEW HOPE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra...

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027

Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end...

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

$15 million payment fulfills previously scheduled tranche under royalty-based financing agreement, bringing...

Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement

Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the...

FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy

Atrioventricular Interval Modulation (“AVIM”) Therapy Food and Drug Administration (“FDA”) Breakthrough Device...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026

Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) set-up data from the MODERATO...

Form 4 - Statement of changes in beneficial ownership of securities

Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update

$106.5 million cash position as of December 31, 2025 to be further enhanced by $35 million expected from...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]